Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948772 | 0.92 | KMT2A (0.44) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL30948674 | 0.91 | MDM4 (0.45) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30948810 | 0.90 | TLR2 (0.42) | KMT2ATLR2CASP3 | |
| SCHEMBL30919280 | 0.88 | PTPN1 (0.44) | TLR2MDM4TP53MDM2 | |
| SCHEMBL30919303 | 0.88 | PTPN1 (0.44) | MDM4TP53MDM2CASP3 | |
| SCHEMBL23447621 | 0.87 | KMT2A (0.44) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL30948715 | 0.86 | MDM4 (0.40) | MDM4TP53MDM2CASP3 | |
| SCHEMBL23446263 | 0.86 | TLR2 (0.49) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL30948717 | 0.85 | MDM4 (0.41) | MDM4TP53MDM2CASP3 | |
| SCHEMBL30919312 | 0.84 | PTPN1 (0.41) | KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | KMT2A 1705/4885TLR2 4416/4885MDM4 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.